EE200300586A - Adenosiini A2A retseptori agonisti ja antikolinergilise vahendi kombinatsioon obstruktiivsete hingamisteede haiguste raviks - Google Patents

Adenosiini A2A retseptori agonisti ja antikolinergilise vahendi kombinatsioon obstruktiivsete hingamisteede haiguste raviks

Info

Publication number
EE200300586A
EE200300586A EEP200300586A EEP200300586A EE200300586A EE 200300586 A EE200300586 A EE 200300586A EE P200300586 A EEP200300586 A EE P200300586A EE P200300586 A EEP200300586 A EE P200300586A EE 200300586 A EE200300586 A EE 200300586A
Authority
EE
Estonia
Prior art keywords
adenosine
treatment
combination
receptor agonist
anticholinergic agent
Prior art date
Application number
EEP200300586A
Other languages
English (en)
Estonian (et)
Inventor
Yeadon Michael
A. Armstrong Roisin
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129275A external-priority patent/GB0129275D0/en
Priority claimed from GB0210238A external-priority patent/GB0210238D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of EE200300586A publication Critical patent/EE200300586A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300586A 2001-05-25 2002-05-24 Adenosiini A2A retseptori agonisti ja antikolinergilise vahendi kombinatsioon obstruktiivsete hingamisteede haiguste raviks EE200300586A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29384201P 2001-05-25 2001-05-25
GB0129275A GB0129275D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination
GB0210238A GB0210238D0 (en) 2002-05-03 2002-05-03 Pharmaceutical composition
PCT/EP2002/005725 WO2002096462A1 (en) 2001-05-25 2002-05-24 An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases

Publications (1)

Publication Number Publication Date
EE200300586A true EE200300586A (et) 2004-04-15

Family

ID=27256345

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300586A EE200300586A (et) 2001-05-25 2002-05-24 Adenosiini A2A retseptori agonisti ja antikolinergilise vahendi kombinatsioon obstruktiivsete hingamisteede haiguste raviks

Country Status (22)

Country Link
US (1) US20040171576A1 (pt)
EP (1) EP1395287A1 (pt)
KR (1) KR20030097901A (pt)
CN (1) CN1535161A (pt)
AP (1) AP2003002911A0 (pt)
BG (1) BG108383A (pt)
BR (1) BR0209986A (pt)
CA (1) CA2448086A1 (pt)
CO (1) CO5540324A2 (pt)
CZ (1) CZ20033126A3 (pt)
EE (1) EE200300586A (pt)
HU (1) HUP0400029A2 (pt)
IL (1) IL158774A0 (pt)
MA (1) MA27028A1 (pt)
MX (1) MXPA03010787A (pt)
NO (1) NO20035202D0 (pt)
OA (1) OA12609A (pt)
PA (1) PA8546101A1 (pt)
PL (1) PL366899A1 (pt)
SK (1) SK14302003A3 (pt)
SV (1) SV2003001055A (pt)
WO (1) WO2002096462A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
NZ556354A (en) 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
DE69932173T2 (de) * 1998-10-16 2007-06-06 Pfizer Inc. Adeninderivate
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
AP2003002911A0 (en) 2003-12-31
EP1395287A1 (en) 2004-03-10
MA27028A1 (fr) 2004-12-20
PL366899A1 (en) 2005-02-07
CA2448086A1 (en) 2002-12-05
SV2003001055A (es) 2003-11-14
MXPA03010787A (es) 2004-03-02
CN1535161A (zh) 2004-10-06
OA12609A (en) 2006-06-09
IL158774A0 (en) 2004-05-12
PA8546101A1 (es) 2003-12-10
BG108383A (bg) 2004-08-31
US20040171576A1 (en) 2004-09-02
NO20035202D0 (no) 2003-11-24
CO5540324A2 (es) 2005-07-29
HUP0400029A2 (hu) 2004-04-28
SK14302003A3 (sk) 2004-08-03
BR0209986A (pt) 2004-04-06
KR20030097901A (ko) 2003-12-31
CZ20033126A3 (cs) 2004-09-15
WO2002096462A1 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
EE200300586A (et) Adenosiini A2A retseptori agonisti ja antikolinergilise vahendi kombinatsioon obstruktiivsete hingamisteede haiguste raviks
EE200300585A (et) PDE4 inhibiitori ja antikolinergilise vahendi kombinatsioon obstruktiivsete hingamisteede haiguste raviks
IL164784A0 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
ZA200503645B (en) Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
AU2002351397A8 (en) Systems and methods using vasoconstriction for improved thermal treatment of tissues
ITMI20000312A0 (it) Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva
AU2002314110A1 (en) Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
HUP0600140A3 (en) Prostaglandine derivatives for the treatment of diseases with bone mass loss having ep4 agonist activity and pharmaceutical compositions thereof
HUP0401987A3 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments
NO20042140L (no) Terapeutiske quionolonforbindelser med 5-HT anatagonistiske egenskaper
AU2003223579A8 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
EP1385465A4 (en) HETEROCYCLIC DERIVATIVE FOR THE TREATMENT OF CANCER AND OTHER PROLIFERATIVE DISEASES
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
EE200300473A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
EE200300474A (et) Tsüano-asendatud dihüdropürimidiinühendid ja nende kasutamine haiguste raviks
NO326689B1 (no) Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene
IL198759A (en) Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety
AU2073502A (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
EE200300328A (et) IL-18 inhibiitorite kasutamine südamehaiguse raviks ja/või ennetamiseks
ITMI20010957A0 (it) Derivati dell'aoe-emodina e loro impiego nel trattamento di patologieneoplastiche
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
NO20083239L (no) Anvendelse av adenosin A2A reseptor agonist for fremstilling av et topisk medikament for å akselerere helingen av et sår
HUP0102388A3 (en) Use of diazepinoindole derivatives for the preparation of pharmaceutical composition treating chronic obstructive pulmonary disease
PL375564A1 (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
DE60220713D1 (de) Ribofuranosyluronamid Derivate als Kristall; ein menschlicher Adenosin A2A Rezeptor Agonsit